Abstract 17018: Prognostic Utility of Plasma galectin-3 Level as a Predictor of Clinical Outcomes in Patients Undergoing Percutaneous Coronary Intervention With Drug-eluting Stents
Background: Galectin-3 is associated with inflammation, cell proliferation, and fibrogenesis. It is well known as a novel biomarker on predictor of cardiovascular events in patients with heart failure. However, the prognostic implications of serum galetin-3 level are unknown in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
Methods A total 2,568 patients undergoing PCI with DES were consecutively enrolled from January 2004 to December 2009. We can analyzed the serum galectin-3 level of 939 patients, and compared major adverse cardiac events (MACE) including all-cause death, nonfatal myocardial infarction, nonfatal stroke and any revascularization according to galectin-3 level.
Results: Median follow up duration was 997 days (interquartile range 766 to 1,264 days). All patients were divided into two groups according to median galectin-3 level (9.52 ng/ml, interquartile range 7.31 to 12.81); high galectin-3 group (n=470) and low galectin-3 group (n=469). High galectin-3 group had significantly higher incidence of all-cause mortality, cardiac death, and composite of MACE. High galectin-3 was a significant independent predictor of MACE (adjusted hazard ratio 1.47, 95% confidence interval 1.13 to 1.92, p=0.005).
Conclusion: The higher galectin-3 is associated higher cardiovascular events in patients undergoing PCI with DES. The serum galectin-3 level may serve as a predictor of cardiovascular events after PCI with DES.
Author Disclosures: S. Seo: None. I. Choi: None. H. Park: None. P. Kim: None. Y. Koh: None. K. Chang: None. J. Kim: None.
- © 2015 by American Heart Association, Inc.